Now showing items 1-2 of 2

    • An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. 

      Melosky, B; Popat, S; Gandara, DR (2018-01)
      The optimal treatment sequence for patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive (EGFR-M+) non-small-cell lung cancer (NSCLC) continues to evolve, related largely to an increasing number ...
    • Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. 

      Petty, RD; Dahle-Smith, A; Stevenson, DAJ; Osborne, A; Massie, D; Clark, C; Murray, GI; Dutton, SJ; Roberts, C; Chong, IY; Mansoor, W; Thompson, J; Harrison, M; Chatterjee, A; Falk, SJ; Elyan, S; Garcia-Alonso, A; Fyfe, DW; Wadsley, J; Chau, I; Ferry, DR; Miedzybrodzka, Z (2017-07-10)
      Purpose The Cancer Esophagus Gefitinib trial demonstrated improved progression-free survival with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib relative to placebo in patients with advanced ...